Ignet

Gene Information

Gene symbol: CCL19

Gene name: chemokine (C-C motif) ligand 19

HGNC ID: 10617

Synonyms: ELC, MIP-3b, exodus-3, CKb11

Related Genes

#	Gene Symbol	Number of hits
1	CCL2	1 hits
2	CCL21	1 hits
3	CCL5	1 hits
4	MAP3K14	1 hits
5	NFKB1	1 hits
6	NFKB2	1 hits
7	RELA	1 hits
8	RELB	1 hits
9	TNFSF12	1 hits

Related Sentences

#	PMID	Sentence
1	20953353	Tumor necrosis factor (TNF) and Fas ligand regulate renal cell survival and inflammation, and therapeutic targeting improves the outcome of experimental renal injury.
2	20953353	TNF-related apoptosis-inducing ligand (TRAIL and its potential decoy receptor osteoprotegerin are the two most upregulated death-related genes in human diabetic nephropathy.
3	20953353	TRAIL activates NF-kappaB in tubular cells and promotes apoptosis in tubular cells and podocytes, especially in a high-glucose environment.
4	20953353	By contrast, osteoprotegerin plays a protective role against TRAIL-induced apoptosis.
5	20953353	Another family member, TNF-like weak inducer of apoptosis (TWEAK induces inflammation and tubular cell death or proliferation, depending on the microenvironment.
6	20953353	While TNF only activates canonical NF-kappaB signaling, TWEAK promotes both canonical and noncanonical NF-kappaB activation in tubular cells, regulating different inflammatory responses.
7	20953353	TWEAK promotes the secretion of MCP-1 and RANTES through NF-kappaB RelA-containing complexes and upregulates CCl21 and CCL19 expression through NF-kappaB inducing kinase (NIK-) dependent RelB/NF-kappaB2 complexes.
8	27353019	However, the downstream effectors of TWEAK/Fn14 in podocytes are poorly characterized.
9	27353019	In cultured podocytes, TWEAK increased the expression of the chemokines CCL21, CCL19 and RANTES in a time-dependent manner.
10	27353019	The inhibitor of canonical NFκB activation parthenolide inhibited the CCL19 and the early RANTES responses, but not the CCL21 or late RANTES responses.
11	27353019	Silencing by a specific siRNA of NIK, the upstream kinase of the non-canonical NFκB pathway, prevented CCL21 upregulation but did not modulate CCL19 or RANTES expression in response to TWEAK, thus establishing CCL21 as a non-canonical NFκB target in podocytes.
12	27353019	Increased kidney Fn14 and CCL21 expression was also observed in rat proteinuric kidney disease induced by puromycin, and was localized to podocytes.
13	27353019	However, the downstream effectors of TWEAK/Fn14 in podocytes are poorly characterized.
14	27353019	In cultured podocytes, TWEAK increased the expression of the chemokines CCL21, CCL19 and RANTES in a time-dependent manner.
15	27353019	The inhibitor of canonical NFκB activation parthenolide inhibited the CCL19 and the early RANTES responses, but not the CCL21 or late RANTES responses.
16	27353019	Silencing by a specific siRNA of NIK, the upstream kinase of the non-canonical NFκB pathway, prevented CCL21 upregulation but did not modulate CCL19 or RANTES expression in response to TWEAK, thus establishing CCL21 as a non-canonical NFκB target in podocytes.
17	27353019	Increased kidney Fn14 and CCL21 expression was also observed in rat proteinuric kidney disease induced by puromycin, and was localized to podocytes.
18	27353019	However, the downstream effectors of TWEAK/Fn14 in podocytes are poorly characterized.
19	27353019	In cultured podocytes, TWEAK increased the expression of the chemokines CCL21, CCL19 and RANTES in a time-dependent manner.
20	27353019	The inhibitor of canonical NFκB activation parthenolide inhibited the CCL19 and the early RANTES responses, but not the CCL21 or late RANTES responses.
21	27353019	Silencing by a specific siRNA of NIK, the upstream kinase of the non-canonical NFκB pathway, prevented CCL21 upregulation but did not modulate CCL19 or RANTES expression in response to TWEAK, thus establishing CCL21 as a non-canonical NFκB target in podocytes.
22	27353019	Increased kidney Fn14 and CCL21 expression was also observed in rat proteinuric kidney disease induced by puromycin, and was localized to podocytes.